Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

August 31, 2015

Study Completion Date

December 31, 2016

Conditions
Chemotherapy Induced Nausea and Vomiting
Interventions
DRUG

granisetron transdermal system

patch

DRUG

Granisetron IV

IV

Trial Locations (12)

32207

Nemours Children's Clinic, Jacksonville

33606

University of South Florida, Tampa

39216

University of Mississippi Medical Center, Jackson

75390

UT Southwestern Medical Center, Dallas

80045

Children's Hospital Colorado, Center for Cancer and Blood Disorders, Aurora

92868

Children's Hospital of Orange County, Orange

98431

Madigan Army Medical Center, Tacoma

99201

Providence Sacred Heart Medical Center and Children's Hospital, Spokane

90095-1690

David Geffen School of Medicine at UCLA, Los Angeles

32610-0296

University of Florida, Gainesville

17033-0850

Penn State Milton S. Hershey Medical Center, Hershey

75390-9063

UTSW/Childrens Medical Center, Dallas

All Listed Sponsors
lead

Kyowa Kirin Pharmaceutical Development Ltd

INDUSTRY

NCT01596400 - Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years | Biotech Hunter | Biotech Hunter